WO2010115629A2 - Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy - Google Patents
Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy Download PDFInfo
- Publication number
- WO2010115629A2 WO2010115629A2 PCT/EP2010/002205 EP2010002205W WO2010115629A2 WO 2010115629 A2 WO2010115629 A2 WO 2010115629A2 EP 2010002205 W EP2010002205 W EP 2010002205W WO 2010115629 A2 WO2010115629 A2 WO 2010115629A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- target
- binding moiety
- amatoxin
- linker
- amanitin
- Prior art date
Links
- 0 CC(C)(CC(C)(C)N*)N Chemical compound CC(C)(CC(C)(C)N*)N 0.000 description 2
- MNEYWQQNBSZTIR-UHFFFAOYSA-N C[O](NC=C)(=C)#C Chemical compound C[O](NC=C)(=C)#C MNEYWQQNBSZTIR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6831—Fungal toxins, e.g. alpha sarcine, mitogillin, zinniol or restrictocin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- the invention relates to tumour therapy.
- the present invention relates to conjugates of a toxin and a target-binding moiety, e.g. an antibody, which are useful in the treatment of cancer.
- the toxin is an amatoxin
- the target-binding moiety is preferably directed against tumour-associated antigens.
- the amatoxin is conjugated to the antibody by linker moieties.
- the linker moieties are covalently bound to functional groups located in positions of the amatoxin proved as preferred positions for the attachment of linkers with respect to optimum antitumor activity.
- the invention relates to pharmaceutical compositions comprising such target-binding moiety toxin conjugates and to the use of such target-binding moiety toxin conjugates for the preparation of such pharmaceutical compositions.
- the target-binding moiety toxin conjugates and pharmaceutical compositions of the invention are useful for the treatment of cancer.
- ADC antibody-drug conjugates
- cytotoxic or cytostatic agents i. e. drugs to kill or inhibit tumor cells in the treatment of cancer
- cytotoxic or cytostatic agents i. e. drugs to kill or inhibit tumor cells in the treatment of cancer
- cytotoxic or cytostatic agents i. e. drugs to kill or inhibit tumor cells in the treatment of cancer
- cytostatic agents i. e. drugs to kill or inhibit tumor cells in the treatment of cancer
- systemic administration of these unconjugated drug agents may result in unacceptable levels of toxicity to normal cells as well as the tumor cells sought to be. Maximal efficacy with minimal toxicity is sought thereby.
- Efforts to design and refine ADC have focused on the selectivity of monoclonal antibodies (mAbs) as well as drug-linking and drug-releasing properties. Both polyclonal antibodies and monoclonal antibodies have been reported as useful in these strategies.
- Amatoxins are cyclic peptides composed of 8 amino acids. They can be isolated from
- Epithelial cell adhesion molecule (EpCAM, CD326) is one of the best-studied target antigens on human tumors (Trzpis et al., 2007; Baeuerle and Gires, 2007). It represents a type I membrane glycoprotein of 314 amino acids with an apparent molecular weight of 40 kDa (Balzar et al., 1999). It is overexpressed in the majority of adenocarcinomas (Winter et al., 2003; Went et al., 2004). In particular, EpCAM expression is enhanced in node-positive breast cancer, epithelial ovarian cancer, cholangiocarcinoma, pancreatic adenocarcinoma and squamous cell head and neck cancer.
- EpCAM is expressed by tumor initiating or cancer stem cells in mammary, colorectal and pancreatic carcinomas (Al-Hajj et al., 2003; Dalerba et al., 2007; Li et al., 2007).
- EpCAM-specific monoclonal antibodies have been used as a diagnostic tool for the detection of rare circulating tumor cells in cancer patients (Allard et al., 2004; Nagrath et al., 2007). A couple of engineered anti-EpCAM antibodies are currently investigated in clinical studies.
- HER2 Her2/neu; ErbB2
- HER2 a receptor tyrosine kinase with an apparent molecular weight of 185 kDa is overexpressed in about 25-30% of human breast cancers and gastric cancers.
- This overexpression which is often due to amplification of the receptor-encoding gene, generally represents a poor prognosis, often involving progressive disease in the years after the initial diagnosis is made.
- Trastuzumab is an IgGl kappa antibody that contains human framework regions with the complementarity-determining regions of a murine antibody (4D5) that binds to HER2.
- Trastuzumab binds to the HER2 antigen and thus inhibits the growth of cancerous cells.
- trastuzumab is a humanized antibody, it minimizes any HAMA response in patients.
- Trastuzumab has been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumor cells that overexpress HER2.
- Trastuzumab is a mediator of antibody-dependent cellular cytotoxicity, ADCC.
- HERCEPTIN ® is clinically active in patients with ErbB2-overexpressing metastatic breast cancers that have received extensive prior anti-cancer therapy. Although HERCEPTIN ® is a breakthrough in treating patients with ErbB2-overexpressing breast cancers that have received extensive prior anti-cancer therapy, the majority of the patients in this population fail to respond or respond only poorly to HERCEPTIN ® treatment. Therefore, there is a significant clinical need for developing further HER2-directed cancer therapies for those patients with HER2-overexpressing tumors or other diseases associated with HER2 expression that do not respond, or respond poorly, to HERCEPTIN ® treatment.
- target-binding moiety toxin conjugates that exert their toxic effects to target cells or tissues at much lower concentration so that the conjugates may be administered at lower concentrations and harmful side effects to non-target cells are minimized.
- the present invention fulfils these and other needs.
- the inventors found out in the experiments underlying the present invention that very effective target-binding moiety toxin conjugates, in particular antibody amatoxin conjugates, can be constructed by choosing particular linkage points in the amatoxin part of the conjugate and by choosing particular linker compounds.
- target-binding moiety toxin conjugates are very effective in that they exert their toxic activity to the target cells at very low concentrations (IC 50 of about 5xlO '12 M) as well as by being highly specific for their target cells.
- IC 50 concentration of about 5xlO '12 M
- these advantages might be explained in that the linkage between the target-binding moiety and the amatoxin or, if present, between the linker and the amatoxin is efficiently cleaved inside the target cell and to a much lesser degree outside the cell.
- the present invention relates to a target-binding moiety toxin conjugate comprising: (i) a target-binding moiety; (ii) at least one amatoxin; and (iii) optionally a linker L2; wherein the at least one amatoxin is connected to the target-binding moiety or, if present, to the linker L2 via the 6' C-atom of amatoxin amino acid 4.
- the present invention relates to a target-binding moiety toxin conjugate comprising: (i) a target-binding moiety; (ii) at least one amatoxin; and (iii) optionally a linker L3; wherein the at least one amatoxin is connected to the target-binding moiety or, if present, to the linker L3 via the ⁇ C-atom of amatoxin amino acid 3.
- the present invention relates to a target-binding moiety toxin conjugate comprising: (i) a target-binding moiety; (ii) at least one amatoxin; and (iii) optionally a linker Ll; wherein the at least one amatoxin is connected to the target-binding moiety or, if present, to the linker Ll via the ⁇ C-atom of amatoxin amino acid 1.
- the present invention relates to the target-binding moiety toxin conjugate according to the first, the second, or the third aspect for use in medicine.
- the present invention relates to the target-binding moiety toxin conjugate according to the first, the second, the third or the fourth aspect for the treatment of cancer or of an autoimmune disease in a patient, wherein the cancer is preferably selected from the group consisting of pancreatic cancer, cholangiocarcinoma, breast cancer, colorectal cancer, lung cancer, prostate cancer, ovarian cancer, stomach cancer, kidney cancer, head and neck cancer, brain tumors, childhood neoplasms, soft tissue sarcomas, epithelial skin cancer, malignant melanoma, leukemia, and malignant lymphoma and wherein the autoimmune disease is preferably selected from the group consisting of Ankylosing Spondylitis, Chagas disease, Crohns Disease, Dermatomyositis, Diabetes mellitus type 1, Goodpasture's syndrome
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising at least one type of target-binding moiety toxin conjugate according to the first, the second, and/or the third aspect and further comprising one or more pharmaceutically acceptable diluents, carriers, excipients, fillers, binders, lubricants, glidants, disintegrants, adsorbents; and/or preservatives.
- Fig. 1 shows the structural formulae of different amatoxins. The numbers in bold type
- (1 to 8) designate the standard numbering of the eight amino acids forming the amatoxin.
- the standard designations of the atoms in amino acids 1 , 3 and 4 are also shown (Greek letters ⁇ to ⁇ , Greek letters ⁇ to ⁇ , and numbers from 1 ' to 7', respectively).
- Fig. 2 shows a comparison of the binding affinities of huHEA125-Ama and huHEA125 to target cells by a binding competition analysis.
- EpCAM-expressing Colo205 cells were incubated with a fixed amount of directly FITC-labeled mouse HEAl 25 antibody. Binding to target cells was analyzed by flow cytometry. Competition of binding with increasing amounts of huHEA125-Ama or huHEA125 revealed a very similar affinity towards the target antigen.
- Fig. 3 shows the surface expression of EpCAM antigen on various carcinoma cell lines detected by indirect immunofluorescence: Fig. 3 A Capan-1; Fig. 3B Colo205; Fig. 3C OZ; and Fig. 3D MCF-7.
- the grey-shaded histograms on the left side of each diagram show the results obtained with control antibody Xolair®; the histograms having a white area on the right side of each diagram show the results obtained with antibody huHEA125.
- the abbreviation FLl-H stands for "fluorescence 1 height" which means the intensity of fluorescence 1, i.e. the green channel for FITC.
- Fig. 4 shows the binding of huHEA125-Amanitin and huHEA125-Phalloidin conjugates to MCF-7 breast cancer cells analyzed by flow cytometry.
- the abbreviation FLl- H stands for "fluorescence 1 height" which means the intensity of fluorescence 1, i.e. the green channel for FITC.
- A bold histogram, huHEA125-Amanitinl; shaded histogram, huHEA125; dotted histogram, Xolair (negative control);
- B bold histogram, huHEA125-Amanitin4; shaded histogram, huHEA125; dotted histogram, Xolair (negative control);
- Fig. 5 shows a comparison of the inhibition of MCF-7 cell proliferation caused by the conjugate huHEA125-Amanitinl, the non-binding control conjugate Xolair-Amanitinl, and free Amanitin.
- Fig. 6 shows a comparison of the inhibition of MCF-7 cell proliferation caused by the conjugate huHEA125-Amanitin4, the conjugate alpha-phalloidin-huHEA125, and free Amanitin.
- Fig. 7 shows a comparison of the inhibition of Capan-1 cell proliferation caused by conjugate huHEA125-Amanitin3, Amanitin-armed control antibody Xolair®, and free Amanitin.
- Fig. 8 shows a comparison of the inhibition of Colo205 cell proliferation caused by conjugate huHEA125-Amanitin3, Amanitin-armed control antibody Xolair®, and free Amanitin.
- Fig. 9 shows a comparison of the inhibition of MCF-7 cell proliferation caused by conjugate huHEA125-Amanitin3, Amanitin-armed control antibody Xolair®, and free Amanitin.
- Fig. 10 shows a comparison of the inhibition of OZ cell proliferation caused by conjugate huHEA125-Amanitin3, Amanitin-armed control antibody Xolair®, and free Amanitin.
- Fig 11 A to D show a comparison of the inhibition on cell proliferation exerted by various ⁇ -amanitin conjugates at different amanitin concentrations using the Her2/neu positive cell lines SKO V-3, SKBR-3 and NCI-N87 as well as the Her2/neu negative cell line MDA-MB231.
- Fig. 12 shows the antitumor activity of various ⁇ -amanitin conjugates at two different concentrations (A: 30 ⁇ g/kg and B: 150 ⁇ g/kg body weight) in an in vivo SKOV-3 xenograft tumor model.
- target-binding moiety refers to any molecule or part of a molecule that can specifically bind to a target molecule or target epitope.
- Preferred target- binding moieties in the context of the present application are (i) antibodies or antigen-binding fragments thereof; (ii) antibody-like proteins; and (iii) nucleic acid aptamers.
- “Target-binding moieties” suitable for use in the present invention typically have a molecular mass of at least 15 kDa, at least 20 kDa, at least 30 kDa or of at least 40 kDa or more.
- an "antibody toxin conjugate” refers to a target-binding moiety toxin conjugate in which the target-binding moiety is an antibody or antigen-binding fragment thereof according to above alternative (i).
- an "antibody-like protein toxin conjugate” refers to a target-binding moiety toxin conjugate in which the target-binding moiety is an antibody-like protein according to above alternative (ii).
- an "aptamer conjugate” refers to a target-binding moiety toxin conjugate in which the target-binding moiety is a nucleic acid aptamer according to above alternative (iii).
- target molecule and “target epitope”, respectively, refers to an antigen and an epitope of an antigen, respectively, that is specifically bound by a target-binding moiety, preferably the target molecule is a tumour- associated antigen, in particular an antigen or an epitope which is present on the surface of one or more tumour cell types in an increased concentration and/or in a different steric configuration as compared to the surface of non-tumour cells or an antigen preferentially expressed on cells involved in autoimmune diseases, examples of such antigens are Immunoglobulin G Fc-part, Thyreotropin-receptor, Type IV Collagen, Proteinase 3, DNA Topoisomerase I, Placoglobin.
- said antigen or epitope is present on the surface of one or more tumour cell types but not on the surface of non-tumour cells.
- tumour associated antigen comprises all substances, which elicit an immune response against a tumour.
- Particular suitable substances are those which are enriched in a tumour cell in comparison to a healthy cell. These substances are preferably present within and/or are accessible on the outside of the tumour cell. If the tumour antigen is only present within a tumour cell, it will still be accessible for the immune system, since the antigen or fragments thereof will be presented by the MHC system at the surface of the cell. In a preferred aspect tumour antigen is almost exclusively present on and/or in the tumour cell and not in a healthy cell of the same cell type.
- Suitable tumour antigens can be identified, for example, by analyzing the differential expression of proteins between tumour and healthy cells of the same cell type using a microarray-based approach (Russo et al, Oncogene. 2003,22 : 6497-507), by PCR- or microarray-based screening for tumor specific mutated cellular genes (Heller, Annu. Rev.
- tumour antigens are selected, which elicit a strong immune response, preferentially a MHC class I immune response.
- Antigens eliciting a strong immune response will induce at least 1%, preferably at least 5%, more preferably at least 10% and most preferably at least 15% IFN- ⁇ -producing CD8 + T or CD4 + T cells isolated from mice previously immunized with the antigen, upon challenge with the antigen and/or will induce preferably at least 5%, and most preferably at least 15% of B-cells cells isolated from mice previously immunized with the antigen, upon challenge with the antigen to proliferate.
- Antigens fulfilling these criterions are candidates for use in therapeutic and/or prophylactic cancer vaccines.
- tumour antigen is selected from the group consisting of T-cell or B-cell-defined cancer-associated antigens belonging to unique gene products of mutated or recombined cellular genes, in particular cyclin-dependent kinases (e.g.
- tumour antigens are antigens derived from HER-2 and EpCAM.
- fragment refers to C- terminally and/or N-terminally deleted proteins, which comprise at least one epitope which can be specifically bound by a target-binding moiety.
- antibody or antigen binding fragment thereof refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e. molecules that contain an antigen binding site that immunospecifically binds an antigen. Also comprised are immunoglobulin-like proteins that are selected through techniques including, for example, phage display to specifically bind to a target molecule, e.g. to the target protein EpCAM or Her2.
- the immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgGl, IgG2, IgG3, IgG4, IgAl and IgA2) or subclass of immunoglobulin molecule.
- Antibodies and antigen-binding fragments thereof suitable for use in the present invention include, but are not limited to, polyclonal, monoclonal, monovalent, bispecific, heteroconjugate, multispecific, human, humanized (in particular CDR-grafted), deimmunized, or chimeric antibodies, single chain antibodies (e.g.
- scFv fragments
- F(ab') 2 fragments fragments produced by a Fab expression library
- diabodies or tetrabodies Holliger P. et al., 1993
- nanobodies anti- idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), and epitope-binding fragments of any of the above.
- the antigen-binding fragments are human antigen-binding antibody fragments of the present invention and include, but are not limited to, Fab, Fab' and F(ab') 2> Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (dsFv) and fragments comprising either a VL or VH domain.
- Antigen-binding antibody fragments, including single-chain antibodies may comprise the variable domain(s) alone or in combination with the entirety or a portion of the following: hinge region, CL, CHl, CH2, and CH3 domains. Also included in the invention are antigen-binding fragments also comprising any combination of variable domain(s) with a hinge region, CL, CHl, CH2, and CH3 domains.
- Antibodies usable in the invention may be from any animal origin including birds and mammals.
- the antibodies are from human, rodent (e.g. mouse, rat, guinea pig, or rabbit), chicken, pig, sheep, goat, camel, cow, horse, donkey, cat, or dog origin. It is particularly preferred that the antibodies are of human or murine origin.
- "human antibodies” include antibodies having the amino acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described for example in U.S. Patent No. 5,939,598 by Kucherlapati & Jakobovits.
- antibody-like protein refers to a protein that has been engineered (e.g. by mutagenesis of loops) to specifically bind to a target molecule.
- an antibody-like protein comprises at least one variable peptide loop attached at both ends to a protein scaffold. This double structural constraint greatly increases the binding affinity of the antibody-like protein to levels comparable to that of an antibody.
- the length of the variable peptide loop typically consists of 10 to 20 amino acids.
- the scaffold protein may be any protein having good solubility properties.
- the scaffold protein is a small globular protein.
- Antibody-like proteins include without limitation affibodies, anticalins, designed ankyrin repeat proteins (for review see: Binz et al.
- Antibody-like proteins can be derived from large libraries of mutants, e.g. be panned from large phage display libraries and can be isolated in analogy to regular antibodies. Also, antibody-like binding proteins can be obtained by combinatorial mutagenesis of surface-exposed residues in globular proteins.
- nucleic acid aptamer refers to a nucleic acid molecule that has been engineered through repeated rounds of in vitro selection or SELEX (systematic evolution of ligands by exponential enrichment) to bind to a target molecule (for a review see: Brody and Gold, 2000).
- the nucleic acid aptamer may be a DNA or RNA molecule.
- the aptamers may contain modifications, e.g. modified nucleotides such as 2 '-fluorine-substituted pyrimidines.
- amatoxin includes all cyclic peptides composed of 8 amino acids as isolated from the genus Amanita and described in ref. (Wieland, T. and Faulstich H., 1978); further all chemical derivatives thereof; further all semisynthetic analogs thereof; further all synthetic analogs thereof built from building blocks according to the master structure of the natural compounds (cyclic, 8 amino acids), further all synthetic or semisynthetic analogs containing non-hydroxylated amino acids instead of the hydroxylated amino acids, further all synthetic or semisynthetic analogs, in which the thioether sulfoxide moiety is replaced by a sulfide, sulfone, or by atoms different from sulfur, e.g.
- amatoxins are defined as peptides or depsipeptides that inhibit mammalian RNA polymerase II.
- Preferred amatoxins are those with a functional group (e.g. a carboxylic group, an amino group, a hydroxy group, a thiol or a thiol-capturing group) that can be reacted with linker molecules or target-binding moieties as defined above.
- Amatoxins which are particularly suitable for the conjugates of the present invention are ⁇ -amanitin, ⁇ - amanitin, ⁇ -amanitin, ⁇ -amanitin, amanin, amaninamide, amanullin, and amanullinic acid as shown in Fig. 1 as well as salts, chemical derivatives, semisynthetic analogs, and synthetic analogs thereof.
- Particularly preferred amatoxins for use in the present invention are ⁇ - amanitin, ⁇ -amanitin, and amaninamide.
- a “chemical derivative” (or short: a “derivative”) of a compound refers to a species having a chemical structure that is similar to the compound, yet containing at least one chemical group not present in the compound and/or deficient of at least one chemical group that is present in the compound.
- the compound to which the derivative is compared is known as the "parent” compound.
- a “derivative” may be produced from the parent compound in one or more chemical reaction steps.
- an “analog” of a compound is structurally related but not identical to the compound and exhibits at least one activity of the compound.
- the compound to which the analog is compared is known as the "parent” compound.
- the afore-mentioned activities include, without limitation: binding activity to another compound; inhibitory activity, e.g. enzyme inhibitory activity; toxic effects; activating activity, e.g. enzyme-activating activity. It is not required that the analog exhibits such an activity to the same extent as the parent compound.
- a compound is regarded as an analog within the context of the present application, if it exhibits the relevant activity to a degree of at least 1% (more preferably at least 5%, more preferably at least 10%, more preferably at least 20%, more preferably at least 30%, more preferably at least 40%, and more preferably at least 50%) of the activity of the parent compound.
- an "analog of an amatoxin” refers to a compound that is structurally related to any one of ⁇ -amanitin, ⁇ -amanitin, ⁇ -amanitin, ⁇ - amanitin, amanin, amaninamide, amanullin, and amanullinic acid as shown in Fig.
- RNA polymerase II that exhibits at least 1% (more preferably at least 5%, more preferably at least 10%, more preferably at least 20%, more preferably at least 30%, more preferably at least 40%, and more preferably at least 50%) of the inhibitory activity against mammalian RNA polymerase II as compared to at least one of ⁇ -amanitin, ⁇ -amanitin, ⁇ -amanitin, ⁇ -amanitin, amanin, amaninamide, amanullin, and amanullinic acid.
- An "analog of an amatoxin" suitable for use in the present invention may even exhibit a greater inhibitory activity against mammalian RNA polymerase II than any one of ⁇ -amanitin, ⁇ -amanitin, ⁇ -amanitin, ⁇ -amanitin, amanin, amaninamide, amanullin, or amanullinic acid.
- the inhibitory activity might be measured by determining the concentration at which 50% inhibition occurs (IC 50 value).
- the inhibitory activity against mammalian RNA polymerase II can be determined indirectly by measuring the inhibitory activity on cell proliferation. A suitable assay for measuring inhibition of cell proliferation is described in Example 3.
- a “semisynthetic analog” refers to an analog that has been obtained by chemical synthesis using compounds from natural sources (e.g. plant materials, bacterial cultures, or cell cultures) as starting material. Typically, a “semisynthetic analog” of the present invention has been synthesized starting from a compound isolated from a mushroom of the Amanita family. In contrast, a “synthetic analog” refers to an analog synthesized by so-called total synthesis from small (typically petrochemical) building blocks. Usually, this total synthesis is carried out without the aid of biological processes.
- a “linker” in the context of the present application refers to a molecule that increases the distance between two components, e.g. to alleviate steric interference between the target- binding moiety and the amatoxin, which may otherwise decrease the ability of the amatoxin to interact with RNA polymerase II.
- the linker may serve another purpose as it may facilitate the release of the amatoxin specifically in the cell being targeted by the target binding moiety. It is preferred that the linker and preferably the bond between the linker and the amatoxin on one side and the bond between the linker and the antibody on the other side is stable under the physiological conditions outside the cell, e.g. the blood, while it can be cleaved inside the cell, in particular inside the target cell, e.g.
- the linker may comprise functionalities that are preferably pH-sensitive to generate pH-sensitive linkers as described, e.g. in S. Fletcher, M. R. Jorgensens and A. D. Miller; Org. Lett. 2004, 6(23), pp 4245-4248, or protease sensitive to generate protease sensitive linkers as described, e.g. in L. DA Ibsen, Blood 2003, 102, 1458-65 or Francisco JA, Cerreny CG, Meyer DL, Nat. Biotechnol 2003, 21, 778-84.
- the bond linking the linker to the target binding moiety may provide the selective stability.
- a linker has a length of at least 1, preferably of 1-20 atoms length (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 atoms) wherein one side of the linker has been reacted with the amatoxin and, the other side with a target-binding moiety.
- 1-20 atoms length e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 atoms
- a linker preferably is a C 1-20 -alkyl, C 1-20 -heteroalkyl, C 2-20 -alkenyl, C 2-20 -heteroalkenyl, C 2-20 - alkynyl, C 2-20 -heteroalkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aralkyl, or a heteroaralkyl group, optionally substituted.
- the linker may contain one or more structural elements such as amide, ester, ether, thioether, disulfide, hydrocarbon moieties and the like. The linker may also contain combinations of two or more of these structural elements.
- each one of these structural elements may be present in the linker more than once, e.g. twice, three times, four times, five times, or six times.
- the linker may comprise a disulfide bond. It is understood that the linker has to be attached either in a single step or in two or more subsequent steps to the amatoxin and the target binding moiety. To that end the linker to be will carry two groups, preferably at a proximal and distal end, which can (i) form a covalent bond to a group, preferably an activated group on an amatoxin or the target binding-peptide or (ii) which is or can be activated to form a covalent bond with a group on an amatoxin.
- linker if the linker is present, it is preferred that chemical groups are at the distal and proximal end of the linker, which are the result of such a coupling reaction, e.g. an ester, an ether, a urethane, a peptide bond etc.
- the presence of a "linker” is optional, i.e. the toxin may be directly linked to a residue of the target-binding moiety in some embodiments of the target-binding moiety toxin conjugate of the present invention. It is preferred that the linker is connected directly via a bond to the targeting moiety, preferably at its terminus. If the target-binding moiety comprises free amino, carboxy or sulfhydryl groups, e.g. in the form of Asp, GIu, Arg, Lys, Cys residues, which may be comprised in a polypeptide, then it is preferred that the linker is coupled to such a group.
- a first compound e.g. an antibody
- a second compound e.g. an antigen, such as a target protein
- K D dissociation constant K D to said second compound of 100 ⁇ M or less, preferably 50 ⁇ M or less, preferably 30 ⁇ M or less, preferably 20 ⁇ M or less, preferably 10 ⁇ M or less, preferably 5 ⁇ M or less, more preferably 1 ⁇ M or less, more preferably 900 nM or less, more preferably 800 nM or less, more preferably 700 nM or less, more preferably 600 nM or less, more preferably 500 nM or less, more preferably 400 nM or less, more preferably 300 nM or less, more preferably 200 nM or less, even more preferably 100 nM or less, even more preferably 90 nM or less, even more preferably 80 nM or less, even more preferably 70 nM or less, even more preferably
- a "patient” means any mammal or bird who may benefit from a treatment with the target-binding moiety toxin conjugates described herein.
- a “patient” is selected from the group consisting of laboratory animals (e.g. mouse or rat), domestic animals (including e.g. guinea pig, rabbit, chicken, pig, sheep, goat, camel, cow, horse, donkey, cat, or dog), or primates including human beings. It is particularly preferred that the "patient” is a human being.
- treat means accomplishing one or more of the following: (a) reducing the severity of the disorder; (b) limiting or preventing development of symptoms characteristic of the disorder(s) being treated; (c) inhibiting worsening of symptoms characteristic of the disorder(s) being treated; (d) limiting or preventing recurrence of the disorder(s) in patients that have previously had the disorder(s); and (e) limiting or preventing recurrence of symptoms in patients that were previously symptomatic for the disorder(s).
- administering includes in vivo administration, as well as administration directly to tissue ex vivo, such as vein grafts.
- an “effective amount” is an amount of a therapeutic agent sufficient to achieve the intended purpose.
- the effective amount of a given therapeutic agent will vary with factors such as the nature of the agent, the route of administration, the size and species of the animal to receive the therapeutic agent, and the purpose of the administration.
- the effective amount in each individual case may be determined empirically by a skilled artisan according to established methods in the art.
- “Pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
- the present invention is directed to a target-binding moiety toxin conjugate comprising: (i) a target-binding moiety; (ii) an amatoxin; and (iii) optionally a linker L2; wherein the amatoxin is connected to the target-binding moiety or, if present, to the linker L2 via the 6' C-atom of amatoxin amino acid 4 (see Fig. 1).
- said amino acid 4 is 2'-sulfur-substituted tryptophan or 2'-sulfur- substituted 6 '-hydroxy-tryptophan.
- the amatoxin is connected to the target- binding moiety or, if present, to the linker L2 via an oxygen atom bound to the 6' C-atom of amatoxin amino acid 4. It is further preferred that the amatoxin is connected to the target- binding moiety or, if present, to the linker L2 via an ether linkage (i.e. amatoxin-O-L2 or amatoxin-0-target-binding moiety). In these embodiments, it is preferred that amino acid 4 is 6 ' -hydroxy-tryptophan.
- the linker L2 is present and the conjugate has the following structure: amatoxin-6'C-O-L2-C(O)-NH-target-binding moiety.
- the present invention is directed to a target-binding moiety toxin conjugate comprising: (i) a target-binding moiety; (ii) an amatoxin; and (iii) optionally a linker L3; wherein the amatoxin is connected to the target-binding moiety or, if present, to the linker L3 via the ⁇ C-atom of amatoxin amino acid 3 (see Fig. 1).
- said amino acid 3 is isoleucine, ⁇ -hydroxy-isoleucine or ⁇ , ⁇ - dihydroxy-isoleucine.
- the amatoxin is connected to the target-binding moiety or, if present, to the linker L3 via an oxygen atom bound to the ⁇ C- atom of amatoxin amino acid 3. It is further preferred that the amatoxin is connected to the target-binding moiety or, if present, to the linker L3 via an ester linkage preferably in the form of an amatoxin-O-C(O)-L3 -target binding boiety or an amatoxin-O-C(O)-target-binding moiety, more preferably an amatoxin- ⁇ C-O-C(O)-L3 -target-binding moiety or an amatoxin- ⁇ C-O-C(O)-target-binding moiety, i.e.
- amino acid 3 is ⁇ , ⁇ -dihydroxy-isoleucine.
- the linker L3 is present and the conjugate has one of the following structures: (i) amatoxin- ⁇ C-O-C(O)-L3-C(O)-NH-target- binding moiety; (ii) amatoxin- ⁇ C-O-L3-C(O)-NH-target-binding moiety; or (iii) amatoxin- ⁇ C-O-C(O)-NH-L3-C(O)-NH-target-binding moiety, i.e.
- amatoxin- ⁇ CH 2 -O-C(O)-L3- C(O)-NH-target-binding moiety (i) amatoxin- ⁇ CH 2 -O-C(O)-L3- C(O)-NH-target-binding moiety; (ii) amatoxin- ⁇ CH 2 -O-L3-C(O)-NH-target-binding moiety; or (iii) amatoxin- ⁇ CH 2 -O-C(O)-NH-L3-C(O)-NH-target-binding moiety.
- the present invention is directed to a target-binding moiety toxin conjugate comprising: (i) a target-binding moiety; (ii) an amatoxin; and (iii) optionally a linker Ll; wherein the amatoxin is connected to the target-binding moiety or, if present, to the linker Ll via the ⁇ C-atom of amatoxin amino acid 1 (see Fig. 1).
- said amino acid 1 is asparagine or aspartic acid.
- the amatoxin is connected to the target- binding moiety or, if present, to the linker Ll via a nitrogen atom bound to the ⁇ C-atom of amatoxin amino acid 1. It is further preferred that the amatoxin is connected to the target- binding moiety or, if present, to the linker Ll via an amide linkage (i.e. amatoxin-C(O)-NH- Ll or amatoxin-C(O)-NH-target-binding moiety; the C-atom in the aforementioned C(O)- moiety is the ⁇ C-atom of amatoxin amino acid 1). In these embodiments, it is preferred that amino acid 1 is asparagine.
- the linker Ll is present and the conjugate has the following structure: amatoxin- ⁇ C(O)-NH-Ll-C(O)-NH-target-binding moiety.
- the amide on the target-binding moiety side of the conjugate is the product of a reaction with a free amino group that was present in the target-binding moiety.
- the target-binding moiety is connected to the amatoxin or, if present, to the linker Ll, L2, or L3 via an amino group present in the target-binding moiety.
- the amatoxin is selected from ⁇ -amanitin, ⁇ -amanitin, ⁇ -amanitin, ⁇ -amanitin, amanin, amaninamide, amanullin, or amanullinic acid (all shown in Fig. 1), as well as salts, chemical derivatives, semisynthetic analogs, and synthetic analogs thereof.
- Particularly preferred amatoxins are ⁇ - amanitin, ⁇ -amanitin, and amaninamide, as well as salts, chemical derivatives, semisynthetic analogs, and synthetic analogs thereof.
- the target binding moiety is in preferred embodiments a protein, in particular an antibody.
- Proteins and in particular antibodies will comprise several amino acids, which allow the coupling of amatoxins.
- Preferred amino acids have free amino, hydroxy, or carbonyl- groups, including Lys, GIn, GIu, Asp, Asn, Thr, and Ser. Accordingly, it is possible to couple more than one amatoxin molecules to one protein molecule.
- An increase of the number of amatoxins per molecule will also increase the toxicity.
- the ratio of protein to amatoxin is between 1 protein molecule to between 1 and 15 amatoxin molecules, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15.
- the dimmer is considered as one molecule. Similar ratios are preferred, if the target binding moiety is not a protein.
- the linker Ll, L2, or L3 has above indicated meaning and preferred meanings.
- the linker Ll, L2, or L3 comprises a disulfide bond.
- the linker Ll, L2, or L3 has a length of 1 to 20 atoms, e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 atoms.
- the length of the linker is defined as the shortest connection - as measured by the number of atoms or bonds - between the toxin moiety and the target-binding moiety.
- the target-binding moiety specifically binds to an epitope that is present on a tumour cell. It is particularly preferred that the target-binding moiety specifically binds to an epitope of T-cell- or B-CeIl- defined cancer-associated antigen belonging to unique gene products of mutated or recombined cellular genes, in particular cyclin-dependent kinases (e.g.
- the target-binding moiety is selected from the group consisting of: (i) antibody or antigen-binding fragment thereof; (ii) antibody-like protein; and (iii) nucleic acid aptamer.
- the antibody or the antigen-binding fragment thereof is selected from a diabody, a tetrabody, a nanobody, a chimeric antibody, a deimmunized antibody, a humanized antibody or a human antibody.
- the antigen binding fragment is selected from the group consisting of Fab, F(ab') 2 , Fd, Fv, single-chain Fv, and disulf ⁇ de-linked Fvs (dsFv).
- the antibody or the antigen binding fragment thereof comprises (a) either the membrane-bound form of the heavy chain of huHEA125 (SEQ ID NO: 1) or the soluble form of the heavy chain of huHEA125 (SEQ ID NO: 2); and/or (b) the light chain of huHEA125 (SEQ ID NO: 11).
- the target-binding moiety toxin conjugate comprises (i) an antibody or an antigen binding fragment thereof specifically binding to epithelial cell adhesion molecule (EpCAM), wherein the antibody or an antigen binding fragment thereof comprises: (a) the heavy chain of huHEA125, wherein the heavy chain is selected from the group consisting of: (al) the membrane-bound form of the heavy chain according to SEQ ID NO: 1, wherein the variable domain of the heavy chain VH as shown in SEQ ID NO: 3 comprises between 0 and 10 (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid exchanges, between 0 and 10 (e.g.
- EpCAM epithelial cell adhesion molecule
- amino acid deletions and/or between 0 and 10 amino acid deletions and/or between 0 and 10 (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid additions positioned in the framework regions of VH, and wherein the constant domain of the heavy chain as shown in SEQ ID NO: 26 comprises between 0 and 10 (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid exchanges, between 0 and 10 (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid deletions and/or between 0 and 10 (e.g.
- variable domain of the heavy chain VH as shown in SEQ ID NO: 3 comprises between 0 and 10 (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid exchanges, between 0 and 10 (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid deletions and/or between 0 and 10 (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid additions positioned in the framework regions of VH
- the constant domain of the heavy chain as shown in SEQ ID NO: 27 comprises between 0 and 10 (e.g.
- amino acid exchanges between 0 and 10 (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid deletions and/or between 0 and 10 (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid additions; and (b) the light chain of huHEA125 according to SEQ ID NO: 11, wherein the variable domain of the light chain VL as shown in SEQ ID NO: 12 comprises between 0 and 10 (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid exchanges, between 0 and 10 (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid deletions and/or between 0 and 10 (e.g.
- the constant domain of the light chain CL as shown in SEQ ID NO: 28 comprises between 0 and 10 (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid exchanges, between 0 and 10 (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid deletions and/or between 0 and 10 (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid additions; (ii) an amatoxin; and (iii) optionally a linker Ll, L2, or L3.
- the target-binding moiety toxin conjugate comprises: (a) the heavy chain of huHEA125, wherein the heavy chain is selected from the group consisting of: (al) the membrane-bound form of the heavy chain according to SEQ ID NO: 1, wherein the variable domain of the heavy chain VH as shown in SEQ ID NO: 3 comprises between 0 and 10 (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid exchanges, between 0 and 10 (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid deletions and/or between 0 and 10 (e.g.
- variable domain of the heavy chain VH as shown in SEQ ID NO: 3 comprises between 0 and 10 (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid exchanges, between 0 and 10 (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid deletions and/or between 0 and 10 (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid additions positioned in the framework regions of VH; and (b) the light chain of huHEA125 according to SEQ ID NO:
- variable domain of the light chain VL as shown in SEQ ID NO: 12 comprises between 0 and 10 (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid exchanges, between 0 and 10 (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid deletions and/or between 0 and 10 (e.g. 0,
- the target-binding moiety toxin conjugate comprises: (a) the heavy chain of huHEA125, wherein the heavy chain is selected from the group consisting of: (al) the membrane-bound form of the heavy chain according to SEQ ID NO: 1, wherein the variable domain of the heavy chain VH as shown in SEQ ID NO: 3 comprises between 0 and 10 (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid exchanges, amino acid deletions and/or amino acid additions positioned in the framework regions of VH, and wherein the constant domain of the heavy chain as shown in SEQ ID NO: 26 comprises between 0 and 10 (e.g.
- variable domain of the heavy chain VH as shown in SEQ ID NO: 3 comprises between 0 and 10 (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid exchanges, amino acid deletions and/or amino acid additions positioned in the framework regions of VH, and wherein the constant domain of the heavy chain as shown in SEQ ID NO: 27 comprises between 0 and 10 (e.g.
- variable domain of the light chain VL as shown in SEQ ID NO: 12 comprises between 0 and 10 (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid exchanges, amino acid deletions and/or amino acid additions positioned in the framework regions of VL
- constant domain of the light chain CL as shown in SEQ ID NO: 28 comprises between 0 and 10 (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid exchanges, amino acid deletions and/or amino acid additions.
- the target-binding moiety toxin conjugate comprises: (a) the heavy chain of huHEA125, wherein the heavy chain is selected from the group consisting of: (al) the membrane-bound form of the heavy chain according to SEQ ID NO: 1, wherein the variable domain of the heavy chain VH as shown in SEQ ID NO: 3 comprises between 0 and 10 (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid exchanges positioned in the framework regions of VH, and wherein the constant domain of the heavy chain as shown in SEQ ID NO: 26 comprises between 0 and 10 (e.g.
- variable domain of the heavy chain VH as shown in SEQ ID NO: 3 comprises between 0 and 10 (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid exchanges positioned in the framework regions of VH, and wherein the constant domain of the heavy chain as shown in SEQ ID NO: 27 comprises between 0 and 10 (e.g.
- variable domain of the light chain VL as shown in SEQ ID NO: 12 comprises between 0 and 10 (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid exchanges positioned in the framework regions of VL
- constant domain of the light chain CL as shown in SEQ ID NO: 28 comprises between 0 and 10 (e.g. 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) amino acid exchanges.
- the target-binding moiety comprises the heavy chain of huHEA125 (membrane-bound form, SEQ ID NO: 1) and/or the light chain of huHEA125 (SEQ ID NO: 11).
- the heavy chain of huHEA125 and/or the light chain of huHEA125 each comprise independently from each other up to 20 (e.g.
- amino acid exchanges, deletions, or additions wherein these amino acid exchanges, deletions, or additions may be positioned in the constant domains of the heavy chain and/or in the constant domain of the light chain and/or in the framework regions of the variable domain of the heavy chain and/or in the framework regions of the variable domain of the light chain.
- the antibody is a complete IgG antibody comprising two heavy chains of huHEA125 (SEQ ID NO: 1) and two light chains of huHEA125 (SEQ ID NO: 11), wherein one heavy chain is connected to one light chain via a disulfide linkage and wherein the heavy chains are connected to each other by one or two (preferably two) disulfide linkages.
- the target-binding moiety comprises the heavy chain of huHEA125 (soluble form, SEQ ID NO: 2) and/or the light chain of huHEA125 (SEQ ID NO: 11).
- the heavy chain of huHEA125 and/or the light chain of huHEA125 each comprise independently from each other up to 20 (e.g.
- amino acid exchanges, deletions, or additions wherein these amino acid exchanges, deletions, or additions may be positioned in the constant domains of the heavy chain and/or in the constant domain of the light chain and/or in the framework regions of the variable domain of the heavy chain and/or in the framework regions of the variable domain of the light chain.
- the antibody is a complete IgG antibody comprising two heavy chains of huHEA125 (SEQ ID NO: 2) and two light chains of huHEA125 (SEQ ID NO: 11), wherein one heavy chain is connected to one light chain via a disulfide linkage and wherein the heavy chains are connected to each other by one or two (preferably two) disulfide linkages.
- the present invention is directed to the target-binding moiety toxin conjugate according to the first, the second, or the third aspect for use in medicine.
- the present invention is directed to the target-binding moiety toxin conjugate according to the first, the second, the third or the fourth aspect for the treatment of cancer or an autoimmune disease in a patient, wherein the cancer is preferably selected from the group consisting of pancreatic cancer, cholangiocarcinoma, breast cancer, colorectal cancer, lung cancer, prostate cancer, ovarian cancer, stomach cancer, kidney cancer, head and neck cancer, brain tumors, childhood neoplasms, soft tissue sarcomas, epithelial skin cancer, malignant melanoma, leukemia, and malignant lymphoma and wherein the autoimmune disease is preferably selected from the group consisting of Ankylosing Spondylitis, Chagas disease, Crohns Disease, Dermatomyositis, Diabetes mellitus type 1, Goodpasture's syndrome,
- the present invention is directed to a pharmaceutical composition
- a pharmaceutical composition comprising at least one type of the target-binding moiety toxin conjugate according to the first, the second, or the third aspect and further comprising one or more pharmaceutically acceptable diluents, carriers, excipients, fillers, binders, lubricants, glidants, disintegrants, adsorbents; and/or preservatives.
- the pharmaceutical composition may comprise two or more different target-binding moiety toxin conjugates.
- the target binding moieties bind to different targets..
- the pharmaceutical composition of the seventh aspect or as prepared in the sixth aspect can be used in the form of systemically administered medicaments.
- parenterals which comprise among others injectables and infusions.
- injectables are formulated either in the form of ampoules or as so called ready-for- use injectables, e.g. ready-to-use syringes or single-use syringes and aside from this in puncturable flasks for multiple withdrawal.
- the administration of injectables can be in the form of subcutaneous (s.c), intramuscular (i.m.), intravenous (i.v.) or intracutaneous (i.e.) application.
- Injectable formulations can further be produced as concentrates, which can be dissolved or dispersed with aqueous isotonic diluents.
- the infusion can also be prepared in form of isotonic solutions, fatty emulsions, liposomal formulations and micro-emulsions. Similar to injectables, infusion formulations can also be prepared in the form of concentrates for dilution. Injectable formulations can also be applied in the form of permanent infusions both in in-patient and ambulant therapy, e.g. by way of mini-pumps.
- parenteral drug formulations for example, albumin, plasma, expander, surface-active substances, organic diluents, pH-influencing substances, complexing substances or polymeric substances, in particular as substances to influence the adsorption of the target-binding moiety toxin conjugates of the invention to proteins or polymers or they can also be added with the aim to reduce the adsorption of the target-binding moiety toxin conjugates of the invention to materials like injection instruments or packaging-materials, for example, plastic or glass.
- parenteral drug formulations for example, albumin, plasma, expander, surface-active substances, organic diluents, pH-influencing substances, complexing substances or polymeric substances, in particular as substances to influence the adsorption of the target-binding moiety toxin conjugates of the invention to proteins or polymers or they can also be added with the aim to reduce the adsorption of the target-binding moiety toxin conjugates of the invention to materials like injection instruments or packaging-materials, for example, plastic or glass.
- target-binding moiety toxin conjugates of the invention can be bound to microcarriers or nanoparticles in parenterals like, for example, to finely dispersed particles based on poly(meth)acrylates, polylactates, polyglycolates, polyamino acids or polyether urethanes.
- Parenteral formulations can also be modified as depot preparations, e.g.
- the target-binding moiety toxin conjugates of the invention are introduced in finely dispersed, dispersed and suspended form, respectively, or as a suspension of crystals in the medicament or based on the "single unit principle” if the target-binding moiety toxin conjugate of the invention is enclosed in a formulation, e.g. in a tablet or a rod which is subsequently implanted.
- a formulation e.g. in a tablet or a rod which is subsequently implanted.
- implants or depot medicaments in single unit and multiple unit formulations often consist of so called biodegradable polymers like e.g. polyesters of lactic acid and glycolic acid, polyether urethanes, polyamino acids, poly(meth)acrylates or polysaccharides.
- Adjuvants and carriers added during the production of the pharmaceutical compositions of the present invention formulated as parenterals are preferably aqua sterilisata (sterilized water), pH value influencing substances like, e.g. organic or inorganic acids or bases as well as salts thereof, buffering substances for adjusting pH values, substances for isotonization like e.g. sodium chloride, sodium hydrogen carbonate, glucose and fructose, tensides and surfactants, respectively, and emulsifiers like, e.g. partial esters of fatty acids of polyoxyethylene sorbitans (for example, Tween ® ) or, e.g.
- aqua sterilisata sterilized water
- pH value influencing substances like, e.g. organic or inorganic acids or bases as well as salts thereof
- buffering substances for adjusting pH values e.g. sodium chloride, sodium hydrogen carbonate, glucose and fructose, tensides and surfactants, respectively
- fatty acid esters of polyoxyethylenes for example, Cremophor ®
- fatty oils like, e.g. peanut oil, soybean oil or castor oil
- synthetic esters of fatty acids like, e.g. ethyl oleate, isopropyl myristate and neutral oil (for example, Miglyol ® ) as well as polymeric adjuvants like, e.g. gelatine, dextran, polyvinylpyrrolidone, additives which increase the solubility of organic solvents like, e.g. propylene glycol, ethanol, N,N-dimethylacetamide, propylene glycol or complex forming substances like, e.g.
- organic solvents e.g. propylene glycol, ethanol, N,N-dimethylacetamide, propylene glycol or complex forming substances like, e.g.
- citrate and urea preservatives like, e.g. benzoic acid hydroxypropyl ester and methyl ester, benzyl alcohol, antioxidants like e.g. sodium sulfite and stabilizers like e.g. EDTA.
- preservatives like, e.g. benzoic acid hydroxypropyl ester and methyl ester, benzyl alcohol, antioxidants like e.g. sodium sulfite and stabilizers like e.g. EDTA.
- thickening agents to prevent the setting of the target- binding moiety toxin conjugates of the invention or, tensides and polyelectrolytes to assure the resuspendability of sediments and/or complex forming agents like, for example, EDTA are added. It is also possible to achieve complexes of the active ingredient with various polymers. Examples of such polymers are polyethylene glycol, polystyrol, carboxymethyl cellulose, Pluronics ® or polyethylene glycol sorbit fatty acid ester.
- the target-binding moiety toxin conjugates of the invention can also be incorporated in liquid formulations in the form of inclusion compounds e.g. with cyclodextrins. In particular embodiments dispersing agents can be added as further adjuvants. For the production of lyophilisates scaffolding agents like mannite, dextran, saccharose, human albumin, lactose, PVP or varieties of gelatine can be used.
- the present invention is directed to a method of treating cancer, or an autoimmune disease
- the cancer is preferably selected from pancreatic cancer, cholangiocarcinoma, breast cancer, colorectal cancer, lung cancer, prostate cancer, ovarian cancer, stomach cancer, kidney cancer, head and neck cancer, brain tumors, childhood neoplasms, soft tissue sarcomas, epithelial skin cancer, malignant melanoma, leukemia, or malignant lymphoma
- the autoimmune disease is preferably selected from the group consisting of Ankylosing Spondylitis, Chagas disease, Crohns Disease, Dermatomyositis, Diabetes mellitus type 1, Goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome (GBS), Hashimoto's disease, Hidradenitis suppurativa, Idiopathic thrombocytopenic purpura, Lupus erythematosus, Mixed Connective Tissue Disease, Myasthenia
- Nucleic acid sequence (annotated according to the IMGT-nomenclature, IGHV/IGHD/IGHJ; IGHD underlined; IGHJ doubly underlined): FRl (SEQ ID NO: 4):
- CDRl (SEQ ID NO: 5): GGATTCGATTTTAGTAGATTCTGG
- TCAAGAGGTATTTCTATGGACTAC FR4 (SEQ ID NO: 10):
- huHEA125 light chain Peptide sequence light chain (IGKV/IGKJ/IGKC; IGKC is underlined) (SEQ ID NO: 11):
- Nucleic acid sequence (annotated according to the IMGT-nomenclature, IGKV/IGKJ; IGKV is underlined; IGKJ is doubly underlined):
- FRI GACATCTTGCTGACTCAGTCTCCAGCCATCCTGTCTGTGAGTCCAGGAGAAAGAGTCA GTTTCTCCTGCAGGGCCAGT
- CDRl (SEQIDNO: 14): CAGAGCATTGGCATAAGT
- CDR2 (SEQ ID NO: 16): TATGCTTCT
- CDR3 (SEQ ID NO: 18: CAACAAAGTAATATCTGGCCAACCACG
- control antibody Xolair® (Omalizumab, human IgGl antibody directed against human IgE immunoglobulin) was produced by Novartis, Germany.
- carcinoma cell lines The following carcinoma cell lines were used for growth inhibition studies with huHE A 125 -amatoxin conj ugates :
- Colo205 colon cancer metastasis
- carcinoma cell lines were used for growth inhibition studies or mouse xenograft studies with HERCEPTIN-amatoxin conjugates:
- MDA-MB231 breast carcinoma Cells were obtained from the American Type Culture Collection (Manassas, USA).
- reaction mixture was applied to 4 tic silica plates (20 x 20 cm) and developed in chloroform/methanol/water (65:25:5).
- ⁇ -amanitin-hexamethylendiamide (II) was dissolved in 144 ⁇ l molecular sieve dried DMF.
- 16.0 ⁇ l solution of DSS (disuccinimidyl suberate; 3.7 mg DSS/lOO ⁇ l DMF) or 16.0 ⁇ l solution of DSP (dithiobis(succinimidyl) propionate; 3.4 mg DSP/lOO ⁇ l DMF) and 3.7 ⁇ l triethylamine have been added respectively. Reaction was performed over night at RT. Reaction products have been precipitated by 2x 30ml dried diethylether and resolubilized in 133 ⁇ l dried DMF.
- the ⁇ -amanitin conjugate with the control antibody Xolair (2mg/ml) was prepared according to the huHEA125 conjugate.
- Ratio toxin : IgG was ca 1 : 1.
- the precipitate of (I) was dissolved in 0.2 ml of DMF, added to 4 ml of huHEA125 (2 mg/ml) in PBS and rotated slowly over night at 5°C. Applied to a Sephadex G25 column (100 x 2cm) developed with PBS, the reaction product was separated from unreacted ⁇ -amanitin and N-hydroxysuccinimide. The toxin load was ca. 1 amanitin per IgG molecule.
- DMSO dimethyl sulfoxide
- Solvent A 95% water: 5% methanol 0.05% trifluoroacetic acid.
- Solvent B 10% water: 90% methanol 0.05% trifluoroacetic acid.
- Gradient 0-5 min 100% A; 5-20 min 0% A; 20-25 min 0% A; 25-27 min 100% A ; 27-30 min 100% A.
- the fractions with the same retention time were collected and the solvents evaporated.
- Solvent A 95% water: 5% methanol 0.05% trifluoroacetic acid.
- Solvent B 10% water: 90% methanol 0.05% trifluoroacetic acid.
- the fractions with the same retention time were collected and the solvents evaporated. 9.10mg (99% yield) of a white powder.
- MS 1019 M+H+; 1041 M+Na+
- DMF 59 ⁇ l (DSS) or 173 ⁇ l (DSP) of the DMF solutions were added to 6.0ml antibody solution (2 mg/ml in PBS). Reaction was performed over night at RT on a rotating shaker. Isolation of the antibody-conjugates (3) and (4) was performed by separation of macromolecular components on a G25-gelfiltration column.
- Solvent A 95% water : 5% methanol 0.05% trifluoroacetic acid.
- Solvent B 10% water: 90% methanol 0.05% trifluoroacetic acid.
- Gradient 0-5 min 100% A; 5-20 min 0% A; 20-25 min 0% A; 25-27 min 100% A ; 27-35 min 100% A. The fractions with the same retention time (20.2 min) were collected and the solvent evaporated.
- Solvent A 95% water : 5% methanol 0.05% trifluoroacetic acid.
- Solvent B 10% water: 90% methanol 0.05% trifluoroacetic acid.
- DCCi N,N-dicyclohexylcarbodimide; 3.4 mg DCCi/80 ⁇ l DMF
- Reaction was performed over night at RT.
- Reaction product was precipitated by 2x 30 ml dried diethylether and resolubilized in 800 ⁇ l dried DMF.
- 266 ⁇ l of the DMF solution was added to 5.0 ml antibody solution (6mg/ml in PBS). Reaction was performed over night at RT on a rotating shaker. Isolation of the antibody-conjugate (7) was performed by separation of macromolecular components on a G25-gelf ⁇ ltration column.
- DMF 122 ⁇ l (DSS) or 176 ⁇ l (DSP) of the DMF solutions were added to 6.0 ml of a solution of Her-2 specific Herceptin antibody (2 mg/ml in PBS). The reaction was performed over night at RT on a rotating shaker. The isolation of the antibody-conjugate (10) and (11), respectively, was performed by separation of macromolecular components on a G25-gelfiltration column.
- ⁇ -amanitin (12) cat.: dibutyl dilaurylstannate n-bu 2 Sn[OCO(CH 2 )i 0 CH 3 ] 2
- Solvent A 95% water : 5% acetonitrile.
- Solvent B 5% water: 95% acetonitrile. Gradient: 0-5 min 100% A; 5-20 min 0% A; 20-25 min 0% A; 25-27 min 100% A; 27-35 min 100%A. The fractions with the same retention time 12-17min were collected and the solvents evaporated .
- HDP compound (13) 10.0 mg HDP compound (13) was dissolved in 100 ⁇ l molecular sieve dried DMF. 80.0 ⁇ l solution of N-hydroxysuccinimide (7.4 mg N-OH-Succ/80 ⁇ l DMF) and 80.0 ⁇ l solution of DCCi (N,N-dicyclohexylcarbodimide; 3.4 mg DCCi/80 ⁇ l DMF) were added. The reaction was performed over night at RT. The reaction product was precipitated by 2x 30 ml dried diethylether and resolubilized in 800 ⁇ l dried DMF. 266 ⁇ l of the DMF solution was added to 5.0 ml antibody solution (6 mg/ml in PBS). Reaction was performed over night at RT on a rotating shaker. The isolation of the antibody-conjugate (14) was performed by separation of macromolecular components on a G25-gelfiltration column.
- the plate was centrifuged (2 min at 2000 rpm) and the supernatant was removed from the cells.
- Cells were re-suspended in 150 ⁇ l of FACS buffer and centrifuged again. After two washing steps by centrifugation, cells were taken up in 100 ⁇ l/well of propidium iodide solution (1 ⁇ g/ml in FACS buffer) allowing discrimination of dead cells. Analysis was performed on a FACScan cytometer (Becton and Dickinson, Heidelberg, Germany) using CellQuest software.
- Binding of huHEA125-amanitin and huHEA125-phalloidin conjugates versus non- conjugated huHEA125 antibody was analyzed by flow cytometry.
- MCF-7 target cells were washed twice in FACS buffer (Dulbecco's PBS with 1 % heat-inactivated fetal calf serum and 0.1 % sodium azide) counted and adjusted to 2x10 7 cells per ml. Fifty ⁇ l of cell suspension was given to each well of a 96 well U-bottom microtiter plate.
- Immunotoxins huHEA125- amanitinl, huHEA125-amanitin4 and huHEA125-phalloidin as well as unconjugated huHEA125 antibody were added at a concentration of 1 ⁇ g/ml in a volume of 100 ⁇ l per well and incubated for 1 h on ice. The plate was centrifuged (2 min at 2000 rpm) and the supernatant was removed from the cells. Cells were re-suspended in 150 ⁇ l of FACS buffer and centrifuged again.
- Example 3 Specific growth inhibition of carcinoma cells by immunoconjugates composed of huHEA125 antibody and amanitin at different binding sites
- Figures 5, 6, and 9 Three examples of growth inhibition induced by different amanitin-IgG conjugates are depicted in Figures 5, 6, and 9.
- Figure 5 shows a comparison of huHEA 125- Amanitin 1 with the non-binding control Xolair- Amanitin 1 and with free Amanitin.
- huHEA125-Amanitin4 was compared with an alpha-phalloidin huHEA125 conjugate and with free Amanitin.
- Figure 9 shows a comparison of huHEA125-Amanitin3 with Amanitin-armed control antibody Xolair and with free Amanitin.
- the IC 5 o of conjugates huHEA125-amanitinl and huHEA125-amanitin4 were both approximately 5xlO '12 M ( Figures 5 and 6) and the IC 5O of conjugate huHEA125-amanitui3 was approximately 2x10 "12 M ( Figure 9).
- the phalloidin-huHEA125 preparation exhibited virtually no effect at least at the dose levels tested (Fig. 6).
- the IC 50 of Amanitin alone is in the range of 10 ' M ( Figures 5, 6, and 9).
- Example 4 Specific growth inhibition of carcinoma cells by immunoconjugates composed of Herceptin antibody and amanitin at different binding sites and using different linking chemistry
- Non conjugated Herceptin showed no cytotoxicity on any cell line while the various amanitin conjugates showed a marked toxicity on the Her2/neu positive cell lines with an EC 50 in the pico- to nanomolar range, no siginifcant toxicity was observed on the Her2/neu negative cell line. (See Figures HA to HD).
- the indicated molar concentration is indicated on the basis of the entire amanitin comprised in the respective conjugate.
- a mouse tumor xenograft model wherein 2.5 x 10 & SKO V-3 ovarial carcinoma cells are implated sub-cutaneously (s.c.) into SCID mice and allowed to grow for 10 days. After 10 days a single dose of 30 ⁇ g/kg body weight (see Figure 12A) or at 150 ⁇ g/kg body weight (see Figure 12B) of various ⁇ -amanitin-Herceptin conjugates (Compounds (15), (3), (4) , (10), (11), and (7)) and non-conjugated Herceptin (Control) were administered intravenously. A clear concentration dependent reduction of tumor growth was observed. Conjugates (7), (10) and (15) led to full tumor remission within the period of observation, i.e. 87 days from the initiation of the experiment.
- Ep-CAM epithelial cell adhesion molecule
- SEQ ID NO: 1 chimeric antibody huHEA125, heavy chain, membrane-bound form
- SEQ ID NO: 2 chimeric antibody huHE A 125, heavy chain, secreted form
- SEQ ID NO: 3 chimeric antibody huHEA125, heavy chain, VH domain
- SEQ ID NO: 4 chimeric antibody huHEA125, heavy chain, FRl segment
- SEQ ID NO: 5 chimeric antibody huHEA125, heavy chain, CDRl segment
- SEQ ID NO: 6 chimeric antibody huHEA125, heavy chain, FR2 segment
- SEQ ID NO: 7 chimeric antibody huHEA125, heavy chain, CDR2 segment
- SEQ ID NO: 8 chimeric antibody huHEA125, heavy chain, FR3 segment
- SEQ ID NO: 9 chimeric antibody huHEA125, heavy chain, CDR3 segment
- SEQ ID NO: 10 chimeric antibody huHEA125, heavy chain, FR4 segment
- SEQ ID NO: 11 chimeric antibody huHEA125
- light chain SEQ ID NO: 12 chimeric antibody huHE A 125, light chain, VL domain
- SEQ ID NO: 13 chimeric antibody huHEA125, light chain, FRl segment
- SEQ ID NO: 14 chimeric antibody huHEA125, light chain, CDRl segment
- SEQ ID NO : 15 chimeric antibody huHE A 125 , light chain, FR2 segment
- SEQ ID NO: 16 chimeric antibody huHEA125, light chain, CDR2 segment
- SEQ ID NO: 17 chimeric antibody huHEA125, light chain, FR3 segment
- SEQ ID NO : 18 chimeric antibody huHE A 125, light chain, CDR3 segment
- SEQ ID NO: 19 chimeric antibody huHEA125, light chain, FR4 segment
- SEQ ID NO: 20 chimeric antibody huHEA125, heavy chain, CDRl domain
- SEQ ID NO : 21 chimeric antibody huHE A 125, heavy chain, CDR2 domain
- SEQ ID NO: 22 chimeric antibody huHEA 125, heavy chain, CDR3 domain
- SEQ ID NO: 23 chimeric antibody huHEA125, light chain, CDRl domain
- SEQ ID NO: 24 chimeric antibody huHEA125, light chain, CDR2 domain
- SEQ ID NO: 25 chimeric antibody huHEA125, light chain, CDR3 domain
- SEQ ID NO: 26 chimeric antibody huHEA125, heavy chain, constant domain, membrane bound form
- SEQ ID NO: 27 chimeric antibody huHEA125, heavy chain, constant domain, secreted form
- SEQ ID NO: 28 chimeric antibody huHEA125, light chain, constant domain
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18214020.2A EP3485912A1 (en) | 2009-04-08 | 2010-04-08 | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy |
EP17158119.2A EP3192529B1 (en) | 2009-04-08 | 2010-04-08 | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy |
AU2010234334A AU2010234334B2 (en) | 2009-04-08 | 2010-04-08 | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy |
US13/263,287 US9233173B2 (en) | 2009-04-08 | 2010-04-08 | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy |
ES10713429.8T ES2621104T3 (en) | 2009-04-08 | 2010-04-08 | Surface binding components of therapeutic cells provided with amatoxin designed for tumor therapy |
CA2758201A CA2758201C (en) | 2009-04-08 | 2010-04-08 | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy |
PL17158119T PL3192529T3 (en) | 2009-04-08 | 2010-04-08 | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy |
EP10713429.8A EP2416804B1 (en) | 2009-04-08 | 2010-04-08 | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy |
US14/954,266 US10513559B2 (en) | 2009-04-08 | 2015-11-30 | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy |
CY20201100329T CY1122855T1 (en) | 2009-04-08 | 2020-04-07 | AMATOXIN CELL SURFACE BINDING THERAPEUTIC INGREDIENTS FOR TUMOR THERAPY |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16769009P | 2009-04-08 | 2009-04-08 | |
US61/167,690 | 2009-04-08 | ||
US22222709P | 2009-07-01 | 2009-07-01 | |
US61/222,227 | 2009-07-01 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/263,287 A-371-Of-International US9233173B2 (en) | 2009-04-08 | 2010-04-08 | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy |
US14/954,266 Continuation US10513559B2 (en) | 2009-04-08 | 2015-11-30 | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010115629A2 true WO2010115629A2 (en) | 2010-10-14 |
WO2010115629A3 WO2010115629A3 (en) | 2010-12-23 |
Family
ID=42269753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2010/002205 WO2010115629A2 (en) | 2009-04-08 | 2010-04-08 | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy |
Country Status (14)
Country | Link |
---|---|
US (2) | US9233173B2 (en) |
EP (3) | EP2416804B1 (en) |
AU (1) | AU2010234334B2 (en) |
CA (3) | CA2970774C (en) |
CY (1) | CY1122855T1 (en) |
DK (1) | DK3192529T3 (en) |
ES (2) | ES2621104T3 (en) |
HR (1) | HRP20200612T1 (en) |
HU (1) | HUE050296T2 (en) |
LT (1) | LT3192529T (en) |
PL (1) | PL3192529T3 (en) |
PT (1) | PT3192529T (en) |
SI (1) | SI3192529T1 (en) |
WO (1) | WO2010115629A2 (en) |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2436398A1 (en) * | 2010-09-30 | 2012-04-04 | Heidelberg Pharma AG | Amatoxin-conjugates with improved linkers |
EP2497499A1 (en) | 2011-03-10 | 2012-09-12 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkages |
EP2684865A1 (en) | 2012-07-13 | 2014-01-15 | Heidelberg Pharma GmbH | Methods for synthesizing amatoxin building block and amatoxins |
WO2014043403A1 (en) * | 2012-09-12 | 2014-03-20 | Agensys, Inc. | Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase |
CN103948872A (en) * | 2014-05-12 | 2014-07-30 | 胡梁谱 | Traditional Chinese medicinal formula for treating psoriatic arthritis |
EP2774624A1 (en) | 2013-03-04 | 2014-09-10 | Heidelberg Pharma GmbH | Amatoxin derivatives |
RU2575854C2 (en) * | 2011-03-10 | 2016-02-20 | Хайдельберг Фарма Гмбх | Amatoxin conjugates with improved bonds |
CN105377304A (en) * | 2014-03-10 | 2016-03-02 | 海德堡医药有限责任公司 | Amatoxin derivatives |
WO2016040868A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anti-cll-1 antibodies and immunoconjugates |
WO2016040856A2 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
WO2016071856A1 (en) | 2014-11-06 | 2016-05-12 | Novartis Ag | Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase |
WO2017023704A1 (en) * | 2015-07-31 | 2017-02-09 | Sutro Biopharma, Inc. | ANTI-EpCAM ANTIBODIES, COMPOSITIONS COMPRISING ANTI-EpCAM ANTIBODIES AND METHODS OF MAKING AND USING ANTI-EpCAM ANTIBODIES |
WO2017046658A1 (en) * | 2016-04-20 | 2017-03-23 | Hangzhou Dac Biotech Co, Ltd | Derivatives of amanita toxins and their conjugation to a cell binding molecule |
WO2017064675A1 (en) | 2015-10-16 | 2017-04-20 | Genentech, Inc. | Hindered disulfide drug conjugates |
WO2017089607A1 (en) | 2015-11-27 | 2017-06-01 | Heidelberg Pharma Gmbh | Derivatives of gamma-amanitin |
CN106810467A (en) * | 2017-01-03 | 2017-06-09 | 苏州昊帆生物股份有限公司 | Diamine compounds list Boc guard methods |
WO2017149077A1 (en) | 2016-03-03 | 2017-09-08 | Heidelberg Pharma Gmbh | Amanitin conjugates |
WO2017191579A1 (en) | 2016-05-05 | 2017-11-09 | Novartis Ag | Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase |
WO2017205741A1 (en) | 2016-05-27 | 2017-11-30 | Genentech, Inc. | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
WO2017219025A1 (en) * | 2016-06-17 | 2017-12-21 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cells |
WO2017219029A3 (en) * | 2016-06-17 | 2018-01-25 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd117+cells |
WO2018027204A1 (en) | 2016-08-05 | 2018-02-08 | Genentech, Inc. | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
WO2018115466A1 (en) | 2016-12-23 | 2018-06-28 | Heidelberg Pharma Research Gmbh | Amanitin antibody conjugates |
US20180289832A1 (en) * | 2017-01-20 | 2018-10-11 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd137+ cells |
WO2019030171A1 (en) | 2017-08-07 | 2019-02-14 | Heidelberg Pharma Gmbh | Novel method for synthesizing amanitins |
WO2019030173A1 (en) | 2017-08-07 | 2019-02-14 | Heidelberg Pharma Gmbh | Novel method for synthesizing amanitins |
WO2019057964A1 (en) | 2017-09-22 | 2019-03-28 | Heidelberg Pharma Research Gmbh | Psma-targeting amanitin conjugates |
US10280225B2 (en) | 2015-04-06 | 2019-05-07 | President And Fellows Of Harvard College | Compositions and methods for non-myeloablative conditioning |
WO2019102435A1 (en) | 2017-11-27 | 2019-05-31 | Euro-Celtique S.A. | Humanized antibodies targeting human tissue factor |
EP3471771A4 (en) * | 2016-05-31 | 2020-04-15 | Sorrento Therapeutics, Inc. | Antibody drug conjugates having derivatives of amatoxin as the drug |
WO2020216947A1 (en) * | 2019-04-24 | 2020-10-29 | Heidelberg Pharma Research Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
US10882915B2 (en) | 2017-10-24 | 2021-01-05 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD117+ cells |
US10899843B2 (en) | 2017-10-24 | 2021-01-26 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD117+ cells |
EP3782654A1 (en) | 2014-09-12 | 2021-02-24 | Genentech, Inc. | Anti-her2 antibodies and immunoconjugates |
WO2021074261A1 (en) * | 2019-10-15 | 2021-04-22 | Heidelberg Pharma Research Gmbh | B-lymphocyte specific amatoxin antibody conjugates |
US20210369854A1 (en) * | 2017-11-29 | 2021-12-02 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd5+ cells |
WO2022058594A1 (en) | 2020-09-18 | 2022-03-24 | Araris Biotech Ag | Transglutaminase conjugation method with amino acid-based linkers |
WO2022084560A1 (en) | 2020-10-25 | 2022-04-28 | Araris Biotech Ag | Means and methods for producing antibody-linker conjugates |
WO2022096604A1 (en) | 2020-11-04 | 2022-05-12 | Heidelberg Pharma Research Gmbh | Composition comprising a combination of immune checkpoint inhibitor and antibody-amatoxin conjugate for use in cancer therapy |
WO2022194988A2 (en) | 2021-03-19 | 2022-09-22 | Heidelberg Pharma Research Gmbh | B-lymphocyte specific amatoxin antibody conjugates |
EP4115910A1 (en) | 2015-03-09 | 2023-01-11 | Heidelberg Pharma Research GmbH | Amatoxin-antibody conjugates |
WO2023072934A1 (en) | 2021-10-25 | 2023-05-04 | Araris Biotech Ag | Methods for producing antibody-linker conjugates |
WO2023161291A1 (en) | 2022-02-22 | 2023-08-31 | Araris Biotech Ag | Peptide linkers comprising two or more payloads |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2011010469A (en) * | 2009-04-08 | 2012-03-14 | Deutsches Krebsforsch | Amatoxin-armed target-binding moieties for the treatment of cancer. |
US10080799B2 (en) * | 2010-02-12 | 2018-09-25 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods and compositions related to glycoprotein-immunoglobulin fusions |
BR112019020049A2 (en) * | 2017-04-06 | 2020-05-12 | Hangzhou Dac Biotech Co., Ltd | CONJUNGED COMPOUND, TUMOR CELL, PHARMACEUTICAL COMPOSITION, AND SYNERGIC AGENTS. |
CN114191564A (en) * | 2017-08-18 | 2022-03-18 | 四川百利药业有限责任公司 | Non-natural amatoxin antibody conjugate |
CN112739340A (en) | 2018-07-23 | 2021-04-30 | 美真达治疗公司 | Use of anti-CD 5 Antibody Drug Conjugates (ADCs) in allogeneic cell therapy |
JP2022533430A (en) * | 2019-05-23 | 2022-07-22 | ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング | Antibody drug conjugates with cleavable linkers |
WO2024121632A1 (en) | 2022-12-09 | 2024-06-13 | Crispr Therapeutics Ag | Use of anti-cd117 antibody drug conjugate (adc) |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69133566T2 (en) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Formation of xenogenic antibodies |
US7009034B2 (en) * | 1996-09-23 | 2006-03-07 | Incept, Llc | Biocompatible crosslinked polymers |
US7229960B2 (en) * | 2000-11-03 | 2007-06-12 | University Of Vermont And State Agricultural College | Methods and compositions for inhibiting GRB7 |
PT1652920E (en) * | 2001-10-01 | 2010-11-08 | Deutsches Krebsforsch | Methods of producing protein libraries and selection of proteins from them |
US6890765B2 (en) * | 2001-11-02 | 2005-05-10 | Roche Diagnostics Operations, Inc. | Particles for immunoassays and methods for treating the same |
EP1661584A1 (en) * | 2004-11-26 | 2006-05-31 | Heinz Dr. Faulstich | Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy |
EP2015782A4 (en) * | 2006-04-12 | 2010-04-07 | Crosslink Genetics Corp | Compositions and methods for modulating gene expression |
EP1859811B1 (en) * | 2006-05-27 | 2011-08-24 | Faulstich, Heinz, Dr. | Use of conjugates of amatoxins or phallotoxins with macromolecules for tumor and inflammation therapy |
EP2436398B1 (en) * | 2010-09-30 | 2013-01-23 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkers |
-
2010
- 2010-04-08 CA CA2970774A patent/CA2970774C/en active Active
- 2010-04-08 ES ES10713429.8T patent/ES2621104T3/en active Active
- 2010-04-08 EP EP10713429.8A patent/EP2416804B1/en active Active
- 2010-04-08 ES ES17158119T patent/ES2784829T3/en active Active
- 2010-04-08 EP EP17158119.2A patent/EP3192529B1/en active Active
- 2010-04-08 WO PCT/EP2010/002205 patent/WO2010115629A2/en active Application Filing
- 2010-04-08 AU AU2010234334A patent/AU2010234334B2/en active Active
- 2010-04-08 PT PT171581192T patent/PT3192529T/en unknown
- 2010-04-08 SI SI201031993T patent/SI3192529T1/en unknown
- 2010-04-08 LT LTEP17158119.2T patent/LT3192529T/en unknown
- 2010-04-08 CA CA3026727A patent/CA3026727C/en active Active
- 2010-04-08 DK DK17158119.2T patent/DK3192529T3/en active
- 2010-04-08 EP EP18214020.2A patent/EP3485912A1/en not_active Withdrawn
- 2010-04-08 CA CA2758201A patent/CA2758201C/en active Active
- 2010-04-08 US US13/263,287 patent/US9233173B2/en active Active
- 2010-04-08 HU HUE17158119A patent/HUE050296T2/en unknown
- 2010-04-08 PL PL17158119T patent/PL3192529T3/en unknown
-
2015
- 2015-11-30 US US14/954,266 patent/US10513559B2/en active Active
-
2020
- 2020-04-07 CY CY20201100329T patent/CY1122855T1/en unknown
- 2020-04-09 HR HRP20200612TT patent/HRP20200612T1/en unknown
Non-Patent Citations (1)
Title |
---|
None |
Cited By (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130259880A1 (en) * | 2010-09-30 | 2013-10-03 | Heidelberg Pharma Gmbh | Amatoxin-Conjugates with Improved Linkers |
RU2601411C2 (en) * | 2010-09-30 | 2016-11-10 | Хайдельберг Фарма Гмбх | Amatoxin-conjugates with improved linkers |
US9399681B2 (en) | 2010-09-30 | 2016-07-26 | Heldelberg Pharma GmbH | Amatoxin-conjugates with improved linkers |
EP2436398A1 (en) * | 2010-09-30 | 2012-04-04 | Heidelberg Pharma AG | Amatoxin-conjugates with improved linkers |
RU2575854C2 (en) * | 2011-03-10 | 2016-02-20 | Хайдельберг Фарма Гмбх | Amatoxin conjugates with improved bonds |
EP2497499A1 (en) | 2011-03-10 | 2012-09-12 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkages |
WO2012119787A1 (en) | 2011-03-10 | 2012-09-13 | Heidelberg Pharma Gmbh | Amatoxin-conjugates with improved linkages |
CN103442736A (en) * | 2011-03-10 | 2013-12-11 | 海德堡医药有限责任公司 | Amatoxin-conjugates with improved linkages |
JP2014508767A (en) * | 2011-03-10 | 2014-04-10 | ハイデルベルク ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング | Amatoxin complex with improved linkage |
KR20140059163A (en) * | 2011-03-10 | 2014-05-15 | 하이델베르크 파마 게엠베하 | Amatoxin-conjugates with improved linkages |
KR101988005B1 (en) * | 2011-03-10 | 2019-06-11 | 하이델베르크 파마 리서치 게엠베하 | Amatoxin-conjugates with improved linkages |
WO2014009025A1 (en) | 2012-07-13 | 2014-01-16 | Heidelberg Pharma Gmbh | Methods for synthesizing amatoxin building block and amatoxins |
CN104470891A (en) * | 2012-07-13 | 2015-03-25 | 海德堡医药有限责任公司 | Methods for synthesizing amatoxin building block and amatoxins |
EP2684865A1 (en) | 2012-07-13 | 2014-01-15 | Heidelberg Pharma GmbH | Methods for synthesizing amatoxin building block and amatoxins |
CN104470891B (en) * | 2012-07-13 | 2016-10-12 | 海德堡医药有限责任公司 | For the method synthesizing amatoxin construction unit and amatoxin |
US9676702B2 (en) | 2012-07-13 | 2017-06-13 | Heidelberg Pharma Gmbh | Methods for synthesizing amatoxin building block and amatoxins |
WO2014043403A1 (en) * | 2012-09-12 | 2014-03-20 | Agensys, Inc. | Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase |
US20150218220A1 (en) * | 2012-09-12 | 2015-08-06 | Brian Alan MENDELSOHN | Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase |
EP2774624A1 (en) | 2013-03-04 | 2014-09-10 | Heidelberg Pharma GmbH | Amatoxin derivatives |
RU2695370C2 (en) * | 2013-03-04 | 2019-07-23 | Хайдельберг Фарма Гмбх | Amatoxin derivatives |
WO2014135282A1 (en) * | 2013-03-04 | 2014-09-12 | Heidelberg Pharma Gmbh | Amatoxin derivatives |
US9982018B2 (en) | 2013-03-04 | 2018-05-29 | Heidelberg Pharma Gmbh | Amatoxin derivatives |
CN105377304A (en) * | 2014-03-10 | 2016-03-02 | 海德堡医药有限责任公司 | Amatoxin derivatives |
CN105377304B (en) * | 2014-03-10 | 2018-05-15 | 海德堡医药有限责任公司 | Amanita hemolysin derivative |
CN103948872A (en) * | 2014-05-12 | 2014-07-30 | 胡梁谱 | Traditional Chinese medicinal formula for treating psoriatic arthritis |
EP3782654A1 (en) | 2014-09-12 | 2021-02-24 | Genentech, Inc. | Anti-her2 antibodies and immunoconjugates |
WO2016040868A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anti-cll-1 antibodies and immunoconjugates |
WO2016040856A2 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
EP3693391A1 (en) | 2014-09-12 | 2020-08-12 | Genentech, Inc. | Anti-cll-1 antibodies and immunoconjugates |
US9938323B2 (en) | 2014-11-06 | 2018-04-10 | Novartis Ag | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase |
WO2016071856A1 (en) | 2014-11-06 | 2016-05-12 | Novartis Ag | Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase |
EP4115910A1 (en) | 2015-03-09 | 2023-01-11 | Heidelberg Pharma Research GmbH | Amatoxin-antibody conjugates |
US10570207B2 (en) | 2015-04-06 | 2020-02-25 | President And Fellows Of Harvard College | Compositions and methods for non-myeloablative conditioning |
US10280225B2 (en) | 2015-04-06 | 2019-05-07 | President And Fellows Of Harvard College | Compositions and methods for non-myeloablative conditioning |
US10906980B2 (en) | 2015-04-06 | 2021-02-02 | President And Fellows Of Harvard College | Compositions and methods for non-myeloablative conditioning |
WO2017023704A1 (en) * | 2015-07-31 | 2017-02-09 | Sutro Biopharma, Inc. | ANTI-EpCAM ANTIBODIES, COMPOSITIONS COMPRISING ANTI-EpCAM ANTIBODIES AND METHODS OF MAKING AND USING ANTI-EpCAM ANTIBODIES |
US11098131B2 (en) | 2015-07-31 | 2021-08-24 | Sutro Biopharma, Inc. | Anti-EpCAM antibodies, compositions comprising anti-EpCAM antibodies and methods of making and using anti-EpCAM antibodies |
WO2017064675A1 (en) | 2015-10-16 | 2017-04-20 | Genentech, Inc. | Hindered disulfide drug conjugates |
WO2017089607A1 (en) | 2015-11-27 | 2017-06-01 | Heidelberg Pharma Gmbh | Derivatives of gamma-amanitin |
EP3222292A1 (en) | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Amanitin conjugates |
WO2017149077A1 (en) | 2016-03-03 | 2017-09-08 | Heidelberg Pharma Gmbh | Amanitin conjugates |
WO2017046658A1 (en) * | 2016-04-20 | 2017-03-23 | Hangzhou Dac Biotech Co, Ltd | Derivatives of amanita toxins and their conjugation to a cell binding molecule |
JP2023051977A (en) * | 2016-04-20 | 2023-04-11 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. | Derivatives of amanita toxins and their conjugation to cell binding molecule |
KR102295190B1 (en) | 2016-04-20 | 2021-08-30 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | Derivatives of Amanita Toxin and Its Binding with Cell Binding Molecules |
KR20180125154A (en) * | 2016-04-20 | 2018-11-22 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | Derivatives of amanitas toxin and its binding with cell binding molecules |
US10836796B2 (en) | 2016-04-20 | 2020-11-17 | Hangzhou Dac Biotech Co., Ltd. | Derivatives of amanita toxins and their conjugation to a cell binding molecule |
US10464969B2 (en) | 2016-05-05 | 2019-11-05 | Novartis Ag | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase |
WO2017191579A1 (en) | 2016-05-05 | 2017-11-09 | Novartis Ag | Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase |
US10604547B2 (en) | 2016-05-05 | 2020-03-31 | Novartis Ag | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase |
WO2017205741A1 (en) | 2016-05-27 | 2017-11-30 | Genentech, Inc. | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
EP3471771A4 (en) * | 2016-05-31 | 2020-04-15 | Sorrento Therapeutics, Inc. | Antibody drug conjugates having derivatives of amatoxin as the drug |
US11013816B2 (en) | 2016-05-31 | 2021-05-25 | Sorrento Therapeutics, Inc. | Antibody drug conjugates having derivatives of amatoxin as the drug |
CN109661400A (en) * | 2016-06-17 | 2019-04-19 | 美真达治疗公司 | For exhausting the composition and method of CD117+ cell |
US10624973B2 (en) | 2016-06-17 | 2020-04-21 | Magenta Therapeutics, Inc. | Methods for the depletion of cells |
US10111966B2 (en) | 2016-06-17 | 2018-10-30 | Magenta Therapeutics, Inc. | Methods for the depletion of CD117+ cells |
WO2017219029A3 (en) * | 2016-06-17 | 2018-01-25 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd117+cells |
CN109641051A (en) * | 2016-06-17 | 2019-04-16 | 美真达治疗公司 | For exhausting the composition and method of cell |
WO2017219025A1 (en) * | 2016-06-17 | 2017-12-21 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cells |
US11046776B2 (en) | 2016-08-05 | 2021-06-29 | Genentech, Inc. | Multivalent and multiepitopic antibodies having agonistic activity and methods of use |
WO2018027204A1 (en) | 2016-08-05 | 2018-02-08 | Genentech, Inc. | Multivalent and multiepitopic anitibodies having agonistic activity and methods of use |
CN110099698B (en) * | 2016-12-23 | 2023-02-17 | 海德堡医药研究有限责任公司 | Amanitin antibody conjugates |
WO2018115466A1 (en) | 2016-12-23 | 2018-06-28 | Heidelberg Pharma Research Gmbh | Amanitin antibody conjugates |
US11446388B2 (en) | 2016-12-23 | 2022-09-20 | Heidelberg Pharma Research Gmbh | Amanitin antibody conjugates |
CN110099698A (en) * | 2016-12-23 | 2019-08-06 | 海德堡医药研究有限责任公司 | Amanitin antibody conjugates |
CN106810467A (en) * | 2017-01-03 | 2017-06-09 | 苏州昊帆生物股份有限公司 | Diamine compounds list Boc guard methods |
US10434185B2 (en) | 2017-01-20 | 2019-10-08 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD137+ cells |
US10576161B2 (en) | 2017-01-20 | 2020-03-03 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD137+ cells |
CN110461876B (en) * | 2017-01-20 | 2024-05-17 | 海德堡医药研究有限责任公司 | Compositions and methods for depleting cd137+ cells |
US20180289832A1 (en) * | 2017-01-20 | 2018-10-11 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd137+ cells |
CN110461876A (en) * | 2017-01-20 | 2019-11-15 | 美真达治疗公司 | For exhausting the composition and method of CD137+ cell |
WO2019030171A1 (en) | 2017-08-07 | 2019-02-14 | Heidelberg Pharma Gmbh | Novel method for synthesizing amanitins |
US11702451B2 (en) | 2017-08-07 | 2023-07-18 | Heidelberg Pharma Research Gmbh | Method for synthesizing amanitins |
US10961277B2 (en) | 2017-08-07 | 2021-03-30 | Heidelberg Pharma Research Gmbh | Method for synthesizing amanitins |
WO2019030173A1 (en) | 2017-08-07 | 2019-02-14 | Heidelberg Pharma Gmbh | Novel method for synthesizing amanitins |
US11420971B2 (en) | 2017-08-07 | 2022-08-23 | Heidelberg Pharma Research Gmbh | Method for synthesizing amanitins |
US11926631B2 (en) | 2017-08-07 | 2024-03-12 | Heidelberg Pharma Research Gmbh | Method of treating cancer using amanitin derivatives |
WO2019057964A1 (en) | 2017-09-22 | 2019-03-28 | Heidelberg Pharma Research Gmbh | Psma-targeting amanitin conjugates |
US10882915B2 (en) | 2017-10-24 | 2021-01-05 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD117+ cells |
US11958908B2 (en) | 2017-10-24 | 2024-04-16 | Crispr Therapeutics Ag | Compositions and methods for the depletion of CD117+ cells |
US11572411B2 (en) | 2017-10-24 | 2023-02-07 | Magenta Therapeutics, Inc. | Anti-CD117 antibodies and conjugates |
US10899843B2 (en) | 2017-10-24 | 2021-01-26 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD117+ cells |
US11401345B2 (en) | 2017-11-27 | 2022-08-02 | Purdue Pharma L.P. | Humanized antibodies targeting human tissue factor |
WO2019102435A1 (en) | 2017-11-27 | 2019-05-31 | Euro-Celtique S.A. | Humanized antibodies targeting human tissue factor |
US20210369854A1 (en) * | 2017-11-29 | 2021-12-02 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd5+ cells |
RU2826004C2 (en) * | 2019-04-24 | 2024-09-03 | Хайдельберг Фарма Ресёрч Гмбх | Amatoxin antibody-drug conjugates and use thereof |
WO2020216947A1 (en) * | 2019-04-24 | 2020-10-29 | Heidelberg Pharma Research Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
WO2021074261A1 (en) * | 2019-10-15 | 2021-04-22 | Heidelberg Pharma Research Gmbh | B-lymphocyte specific amatoxin antibody conjugates |
WO2022058594A1 (en) | 2020-09-18 | 2022-03-24 | Araris Biotech Ag | Transglutaminase conjugation method with amino acid-based linkers |
US12076412B2 (en) | 2020-10-25 | 2024-09-03 | Araris Biotech Ag | Antibody-drug conjugates through specific linker oligopeptides |
WO2022084560A1 (en) | 2020-10-25 | 2022-04-28 | Araris Biotech Ag | Means and methods for producing antibody-linker conjugates |
WO2022096604A1 (en) | 2020-11-04 | 2022-05-12 | Heidelberg Pharma Research Gmbh | Composition comprising a combination of immune checkpoint inhibitor and antibody-amatoxin conjugate for use in cancer therapy |
WO2022194988A2 (en) | 2021-03-19 | 2022-09-22 | Heidelberg Pharma Research Gmbh | B-lymphocyte specific amatoxin antibody conjugates |
WO2023072934A1 (en) | 2021-10-25 | 2023-05-04 | Araris Biotech Ag | Methods for producing antibody-linker conjugates |
WO2023161291A1 (en) | 2022-02-22 | 2023-08-31 | Araris Biotech Ag | Peptide linkers comprising two or more payloads |
Also Published As
Publication number | Publication date |
---|---|
EP2416804B1 (en) | 2017-03-01 |
US10513559B2 (en) | 2019-12-24 |
DK3192529T3 (en) | 2020-04-20 |
CA2758201A1 (en) | 2010-10-14 |
EP3192529A1 (en) | 2017-07-19 |
AU2010234334B2 (en) | 2014-10-09 |
CA3026727A1 (en) | 2010-10-14 |
EP3485912A1 (en) | 2019-05-22 |
CA2758201C (en) | 2017-08-01 |
ES2784829T3 (en) | 2020-10-01 |
SI3192529T1 (en) | 2020-07-31 |
CA3026727C (en) | 2022-03-22 |
EP3192529B1 (en) | 2020-03-25 |
ES2621104T3 (en) | 2017-07-03 |
US20160089450A1 (en) | 2016-03-31 |
HUE050296T2 (en) | 2020-11-30 |
CY1122855T1 (en) | 2021-05-05 |
US20120100161A1 (en) | 2012-04-26 |
AU2010234334A1 (en) | 2011-11-10 |
EP2416804A2 (en) | 2012-02-15 |
US9233173B2 (en) | 2016-01-12 |
HRP20200612T1 (en) | 2020-08-07 |
LT3192529T (en) | 2020-06-25 |
CA2970774A1 (en) | 2010-10-14 |
CA2970774C (en) | 2019-01-08 |
PL3192529T3 (en) | 2020-08-24 |
WO2010115629A3 (en) | 2010-12-23 |
PT3192529T (en) | 2020-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10513559B2 (en) | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy | |
EP2416805B1 (en) | Amatoxin antibody conjugates for the treatment of cancer | |
CA2829421C (en) | Amatoxin-conjugates with improved linkages | |
EP2964264B1 (en) | Amatoxin derivatives | |
US8568727B2 (en) | Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them | |
JP6321687B2 (en) | Amatoxin derivatives | |
CN105377307A (en) | Antibody-drug conjugate having improved stability and use thereof | |
AU2018286601B2 (en) | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy | |
FAULSTICH et al. | Patent 2758201 Summary |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10713429 Country of ref document: EP Kind code of ref document: A2 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2758201 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 7773/DELNP/2011 Country of ref document: IN |
|
REEP | Request for entry into the european phase |
Ref document number: 2010713429 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010713429 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2010234334 Country of ref document: AU Date of ref document: 20100408 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13263287 Country of ref document: US |